Jinling Pharmaceutical released its 2026 interim report, with total operating revenue of 1.584 billion yuan and net profit attributable to the parent of 50.3825 million yuan, an increase of 2.0489 million yuan compared with the same period last year, up 4.24% year-on-year. Net cash inflow from operating activities was 247 million yuan, up 1461.39% year-on-year. The company's asset-liability ratio was 19.64%, gross margin was 22.38%, rising for six consecutive quarters, and ROE was 1.34%. Inventory turnover ranked first among peers, and the number of shareholders was 39,300.
Jinling Pharmaceutical Co LtdNet profit up 4.24% year-on-year, with strong operating cash flow and improving gross margin.
